Determination of Risk Factors for Severe Life-Threatening Course of Multisystem Inflammatory Syndrome Associated with COVID-19 in Children

Multisystem inflammatory syndrome associated with COVID-19 in children (MIS-C) is a life-threatening condition that often requires intensive care unit (ICU) admission. The aim of this study was to determine risk factors for severe/life-threatening course of MIS-C. The study included 166 patients (99 boys, 67 girls) aged 4 months–17 years (median 8.2 years). The criterion of severity was the fact of ICU admission. To conduct a comparative analysis, MIS-C patients were divided into two groups: patients hospitalized in the ICU (n = 84, 50.6%) and those who did not need ICU admission (n = 82, 49.4%). Patients with a more severe course of MIS-C were significantly older. They had a higher frequency of signs such as rash, swelling, hepatomegaly, splenomegaly, and neurological and respiratory symptoms. Hypotension/shock and myocardial involvement were much more common in patients with severe MIS-C. These patients had a more significant increase in CRP, creatinine, troponin, and D-dimer levels. Additionally, the presence of macrophage activation syndrome was higher in patients admitted to the ICU. Conclusion: Nineteen predictors of severe course of MIS-C were found, out of which hepatomegaly, splenomegaly, D-dimer > 2568 ng/mL, troponin > 10 pg/mL were mainly associated with the probability of being classified as early predictors of severe MIS-C requiring ICU admission.

[1]  A. Randolph,et al.  Variation in Early Anakinra Use and Short‐Term Outcomes in Multisystem Inflammatory Syndrome in Children , 2023, Arthritis & rheumatology.

[2]  J. Książyk,et al.  Clinical characteristics of children with MIS-C fulfilling classification criteria for macrophage activation syndrome , 2022, Frontiers in Pediatrics.

[3]  O. Kalashnikova,et al.  Heart Involvement in Multisystem Inflammatory Syndrome, Associated With COVID-19 in Children: The Retrospective Multicenter Cohort Data , 2022, Frontiers in Pediatrics.

[4]  G. Brisca,et al.  Timely Recognition and Early Multi-Step Antinflammatory Therapy May Prevent ICU Admission of Patients With MIS-C: Proposal for a Severity Score , 2021, Frontiers in Pediatrics.

[5]  O. Kalashnikova,et al.  Distinguishing Between Multisystem Inflammatory Syndrome, Associated With COVID-19 in Children and the Kawasaki Disease: Development of Preliminary Criteria Based on the Data of the Retrospective Multicenter Cohort Study , 2021, Frontiers in Pediatrics.

[6]  I. Rabbone,et al.  MIS-C Treatment: Is IVIG Always Necessary? , 2021, Frontiers in Pediatrics.

[7]  S. Özen,et al.  Differences and similarities of multisystem inflammatory syndrome in children, Kawasaki disease and macrophage activating syndrome due to systemic juvenile idiopathic arthritis: a comparative study , 2021, Rheumatology International.

[8]  R. Cron,et al.  Performance of Cytokine Storm Syndrome Scoring Systems in Pediatric COVID‐19 and Multisystem Inflammatory Syndrome in Children , 2021, ACR open rheumatology.

[9]  M. Oster,et al.  Racial and Ethnic Disparities in Multisystem Inflammatory Syndrome in Children in the United States, March 2020 to February 2021 , 2021, The Pediatric infectious disease journal.

[10]  Manish M Patel,et al.  Multisystem Inflammatory Syndrome in Children — Initial Therapy and Outcomes , 2021, The New England journal of medicine.

[11]  D. Walt,et al.  Multisystem inflammatory syndrome in children is driven by zonulin-dependent loss of gut mucosal barrier. , 2021, The Journal of clinical investigation.

[12]  R. Sanders,et al.  High titers and low fucosylation of early human anti-SARS-CoV-2 IgG promote inflammation by alveolar macrophages , 2021, Science Translational Medicine.

[13]  G. Zuccotti,et al.  Defining Kawasaki disease and pediatric inflammatory multisystem syndrome-temporally associated to SARS-CoV-2 infection during SARS-CoV-2 epidemic in Italy: results from a national, multicenter survey , 2021, Pediatric Rheumatology.

[14]  M. Oster,et al.  Factors linked to severe outcomes in multisystem inflammatory syndrome in children (MIS-C) in the USA: a retrospective surveillance study , 2021, The Lancet Child & Adolescent Health.

[15]  Manish M Patel,et al.  Characteristics and Outcomes of US Children and Adolescents With Multisystem Inflammatory Syndrome in Children (MIS-C) Compared With Severe Acute COVID-19. , 2021, JAMA.

[16]  A. Belot,et al.  Association of Intravenous Immunoglobulins Plus Methylprednisolone vs Immunoglobulins Alone With Course of Fever in Multisystem Inflammatory Syndrome in Children. , 2021, JAMA.

[17]  L. Henderson,et al.  American College of Rheumatology Clinical Guidance for Multisystem Inflammatory Syndrome in Children Associated With SARS–CoV‐2 and Hyperinflammation in Pediatric COVID‐19: Version 2 , 2020, Arthritis & rheumatology.

[18]  D. De Wolf,et al.  Acute Cardiovascular Manifestations in 286 Children with Multisystem Inflammatory Syndrome Associated with COVID-19 Infection in Europe. , 2020, Circulation.

[19]  A. García-Salido,et al.  Shock and Myocardial Injury in Children With Multisystem Inflammatory Syndrome Associated With SARS-CoV-2 Infection: What We Know. Case Series and Review of the Literature , 2020, Journal of intensive care medicine.

[20]  P. Zachariah,et al.  Multisystem Inflammatory Syndrome in Children Associated With Coronavirus Disease 2019 in a Children's Hospital in New York City: Patient Characteristics and an Institutional Protocol for Evaluation, Management, and Follow-Up. , 2020, Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies.

[21]  S. Tibby,et al.  A national consensus management pathway for paediatric inflammatory multisystem syndrome temporally associated with COVID-19 (PIMS-TS): results of a national Delphi process , 2020, The Lancet Child & Adolescent Health.

[22]  K. Wilson,et al.  Mapping Systemic Inflammation and Antibody Responses in Multisystem Inflammatory Syndrome in Children (MIS-C) , 2020, Cell.

[23]  F. Haerynck,et al.  Multisystem inflammatory syndrome in children related to COVID-19: a systematic review , 2020, European Journal of Pediatrics.

[24]  M. Malim,et al.  Peripheral immunophenotypes in children with multisystem inflammatory syndrome associated with SARS-CoV-2 infection , 2020, Nature Medicine.

[25]  K. Reilly,et al.  COVID-19–Associated Multisystem Inflammatory Syndrome in Children — United States, March–July 2020 , 2020, MMWR. Morbidity and mortality weekly report.

[26]  J. Chou,et al.  Distinct clinical and immunological features of SARS-COV-2-induced multisystem inflammatory syndrome in children. , 2020, The Journal of clinical investigation.

[27]  P. Davies,et al.  Intensive care admissions of children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS) in the UK: a multicentre observational study , 2020, The Lancet Child & Adolescent Health.

[28]  David R. Holtgrave,et al.  Multisystem Inflammatory Syndrome in Children in New York State , 2020, The New England journal of medicine.

[29]  Michael Levin,et al.  Childhood Multisystem Inflammatory Syndrome — A New Challenge in the Pandemic , 2020, The New England journal of medicine.

[30]  Simon Li,et al.  Multisystem Inflammatory Syndrome in U.S. Children and Adolescents , 2020, The New England journal of medicine.

[31]  G. Carcelain,et al.  Paediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2 mimicking Kawasaki disease (Kawa-COVID-19): a multicentre cohort , 2020, Annals of the Rheumatic Diseases.

[32]  P. Davies,et al.  Clinical Characteristics of 58 Children With a Pediatric Inflammatory Multisystem Syndrome Temporally Associated With SARS-CoV-2. , 2020, JAMA.

[33]  Angelo Mazza,et al.  An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study , 2020, The Lancet.

[34]  Naira M Mustafa,et al.  Characterisation of COVID-19 Pandemic in Paediatric Age Group: A Systematic Review and Meta-Analysis , 2020, Journal of Clinical Virology.

[35]  F. Rovida,et al.  Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in Children and Adolescents: A Systematic Review. , 2020, JAMA pediatrics.

[36]  S. Maskatia,et al.  COVID-19 and Kawasaki Disease: Novel Virus and Novel Case. , 2020, Hospital pediatrics.

[37]  J. Ludvigsson Systematic review of COVID‐19 in children shows milder cases and a better prognosis than adults , 2020, Acta paediatrica.

[38]  B. McCrindle,et al.  Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A Scientific Statement for Health Professionals From the American Heart Association , 2017, Circulation.

[39]  C. Wouters,et al.  2016 Classification Criteria for Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis , 2016, Annals of the rheumatic diseases.

[40]  G. Hejblum,et al.  Development and Validation of the HScore, a Score for the Diagnosis of Reactive Hemophagocytic Syndrome , 2014, Arthritis & rheumatology.

[41]  M. Aricò,et al.  HLH‐2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis , 2007, Pediatric blood & cancer.

[42]  A. Martini,et al.  Preliminary diagnostic guidelines for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. , 2005, The Journal of pediatrics.

[43]  OUP accepted manuscript , 2021, Clinical Infectious Diseases.